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Objectives. With this study, we sought to examine the hetero-
geneity of cardiac allograft vasculopathy in vivo using coronary
angioscopy as an adjunct to intravascular ultrasound, and we
evaluated the clinical relations of immunologic and nonimmuno-
logic risk factors with the different forms of cardiac allograft
vasculopathy detected angioscopically.
Background. Intravascular ultrasound detects vascular intimal
proliferation accurately but is limited in its ability to delineate
morphologic characteristics. Coronary angioscopy can evaluate
intimal surface morphology by direct visualization and can differ-
entiate pathologically distinct forms of plaque topography on the
basis of color and contour.
Methods. We studied 107 consecutive heart transplant recipi-
ents with intravascular ultrasound and angioscopy at the time of
their annual angiogram, and we assessed the relation of nonim-
munologic and immunologic risk factors to the development of
cardiac allograft vasculopathy distinguished angioscopically into
a pigmented (yellow) or nonpigmented (white) intimal thickening.
We further evaluated the clinical differences in cardiac events
among these two forms of angioscopically heterogeneous forms of
cardiac allograft vasculopathy.
Results. Significant clinical predictors of nonpigmented intimal
thickening were advanced donor age and lower mean cyclosporine
levels, whereas hyperlipidemia, cumulative prednisone dose and
time since transplantation correlated with pigmented intimal
hyperplasia. In addition, comparisons between the two angio-
scopic groups revealed increased intimal thickening, serum cho-
lesterol, low density lipoprotein cholesterol, acute allograft rejec-
tion and time since transplantation in the group with pigmented
intimal thickening (p < 0.05). With regard to cardiac events,
nonpigmented plaque was more frequently found in the sudden
death group (53% vs. 20%, p 5 0.05), whereas the nonsudden
cardiac event group had a significantly higher prevalence of
pigmented plaque (80% vs. 47%, p 5 0.07).
Conclusions. These findings indicate that cardiac allograft
vasculopathy is a heterogeneous disease with varied morphologic
expressions with different clinical implications. Furthermore, this
investigation provides insight into the cohesive, yet diverse influ-
ences of various factors, particularly immunosuppression, in
these forms of cardiac allograft vasculopathy.
(J Am Coll Cardiol 1997;29:1339–44)
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Necropsy studies of failed cardiac allografts have alluded to the
heterogeneous nature of cardiac allograft vasculopathy (1,2).
Indeed, histopathologic analyses have revealed that the mor-
phologic expression of cardiac allograft vasculopathy may
range from concentric, diffuse intimal hyperplasia to fibrofatty
plaques indistinguishable from spontaneously occurring ath-
erosclerosis. These important observations have raised several
questions. First, are there distinct types of cardiac allograft
vasculopathy influenced by diverse pathogenic factors? Sec-
ond, do these distinct forms of cardiac allograft vasculopathy
have different clinical implications for the individual heart
transplant patient?
Intravascular ultrasound and intracoronary angioscopy
have revolutionized the in vivo morphologic characterization
of the coronary vasculature in heart transplant recipients (3,4).
Although intravascular ultrasound allows accurate detection of
myointimal hyperplasia, it is inherently limited in its ability to
provide detailed plaque characterization (5). In contrast, in-
tracoronary angioscopy can evaluate intimal surface morphol-
ogy by direct visualization and can therefore complement
ultrasound examination by providing insight into plaque color
and contour. Thus, angioscopic assessment of the coronary
vasculature in heart transplant recipients has shown that two
distinct morphologic types of intimal hyperplasia can be de-
tected. These include a nonpigmented (white, “fibrous”) and a
pigmented (yellow, “lipid-laden”) variety (Fig. 1) (5).
The purpose of this study was several-fold: 1) to examine
the heterogeneity of cardiac allograft vasculopathy in vivo
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using coronary angioscopy as an adjunct to intravascular
ultrasound; 2) to evaluate the clinical relations of immunologic
and nonimmunologic risk factors on the various forms of
cardiac allograft vasculopathy; and 3) to delineate whether
angioscopically detected morphologic differences were associ-
ated with differences in the type of morbid cardiac events in
heart transplant recipients.
Methods
Patients. The study group consisted of a consecutive co-
hort of 107 heart transplant recipients (92 men and 15 women)
aged 49 6 11 years (range 22 to 68) who underwent intravas-
cular ultrasound and intracoronary angioscopy at the time of
annual coronary angiography and at 2.5 6 1.6 years after heart
transplantation between January 1990 and April 1994. Twenty-
nine of the first 107 patients included in this cohort were used
in a previous investigation that examined the different mor-
phologic characteristics of the coronary surface by angioscopy
and ultrasound (5). However, clinical correlates and clinical
outcomes were not previously examined in that report because
of the small number of patients (5). All recipients received
identical triple immunosuppressive therapy (cyclosporine,
prednisone and azathioprine) and were free of acute rejection
and infection at the time of the annual ultrasound and
angioscopic study. Patients were excluded from the study if
they were ineligible for cardiac catheterization or if they died
during their hospital stay. Written, informed consent was
obtained from all patients, and the study was approved by the
Institutional Review Board.
Immunologic risk factors. Episodes of cellular or humoral
rejection requiring treatment, as well as the number of human
leukocyte antigen (HLA)-A, -B, or -DR matches between the
donor and recipient, were examined in all patients. Further-
more, we performed a detailed analysis of immunosuppressive
regimens, including average cyclosporine dose (mg/kg body
weight per day), mean cyclosporine levels (pg/dl), average daily
prednisone dose (mg/kg per day), cumulative prednisone con-
sumption for the duration of allograft survival (g), average
daily azathioprine dose (mg/kg per day) and use of induction
OKT3.
Nonimmunologic risk factors. Donor age, gender, obesity
indexes (percent weight gain after transplantation), hyperten-
sion, history of cytomegalovirus infection requiring therapeutic
intervention with intravenous ganciclovir, fasting lipid profile
(triglyceride, total cholesterol, low density lipoprotein choles-
terol and high density lipoprotein cholesterol levels) at the
time of ultrasound examination, diabetes mellitus, ischemic
time and years since transplantation were assessed in all heart
transplant recipients.
Intravascular ultrasound. Coronary ultrasound was per-
formed during routine annual coronary angiography as previ-
ously reported (6,7). After administration of 200 mg of intra-
coronary nitroglycerin, the ultrasound catheter was positioned
in the distal segment of the target vessel over a 0.014-in.
(0.036-cm) guide wire. This one target vessel was selected by
the presence of at least three easily definable and reproducible
branch points to assist in the accurate and serial assessment of
three regions of interest. The guide wire was removed, and the
ultrasound catheter was advanced to the distal end of the
ultrasound sheath under fluoroscopic guidance. The drive
module was then engaged, and continuous images of the
coronary artery were obtained as the ultrasound transducer
was slowly withdrawn. In addition, fluoroscopic pictures and
audio annotations were used to ensure the correct localization
of the artery segment for subsequent off-line analysis. Guiding
catheter pressure, ST segment changes and cardiac rhythm
were continuously monitored during the procedure. After
Figure 1. Intracoronary angioscopic images demonstrat-
ing normal (white, glistening), pigmented (yellow) and
nonpigmented (white, dull) plaques in heart transplanta-
tion.
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ultrasound images were obtained, the transducer and sheath
were removed, and a final angiogram was obtained to confirm
the patency of the coronary vessel. No complications related to
the intravascular ultrasound were encountered.
Coronary ultrasound assessment. Intravascular ultrasound
measurements were performed by one investigator who had no
knowledge of the previous assessment of risk factors. Three
coronary sites per vessel (proximal, mid and distal), for a total
of 321 coronary artery segments, were evaluated. Maximal
intimal thickness and intimal area were obtained by tracing the
lumen vessel wall interface and the external border of the
intimal layer. The intimal index was calculated as the ratio of
the intimal area to the total vessel area. Lesions were further
assessed with regard to the plaque location, morphology and
eccentricity.
Intracoronary angioscopy. Angioscopy was performed
during routine annual coronary angiography as previously
reported (5). In brief, the angioscopic catheter (Imagecath,
Baxter Healthcare) contains channels for the inflation and
deflation of a distal occlusive balloon, as well as channels that
contain illuminating and imaging fibers. In addition, a lumen
accommodates a 0.014-in. guide wire and enables infusion of
flush solution to keep the lumen free of blood to achieve a clear
viewing field. The distal balloon is designed to occlude flow when
inflated to 1 to 2 atm. Angioscopic images were obtained by
imaging the coronary artery (previously examined by intravascu-
lar ultrasound) for 45 s during balloon occlusion while infusing up
to 10 ml of crystalloid solution. These images were recorded and
stored on videotape for review and archiving. Guiding catheter
pressure, ST segment changes, cardiac rhythm and patient com-
fort were monitored continuously during angioscopy.
Angioscopy assessment. Angioscopic images were exam-
ined in blinded manner by two observers (C.J.W., T.J.C. or
S.P.J.) who evaluated the archived recordings for the presence
of a pigmented (yellow) or nonpigmented (white) plaque,
classified according to the predominance of surface pigmenta-
tion in the vessel studied. These morphologic findings were
further classified on the basis of surface texture being smooth
contour or irregular (undulating, corrugated appearance).
Interobserver and intraobserver variability. Ten random
studies were selected, and corresponding angioscopic and
ultrasound images were measured two different times by one
observer and separately by two observers (C.J.W., T.J.C. or
S.P.J.). The data were used for evaluating interobserver vari-
ability in delineating the surface morphology of the plaque and
in measuring intimal thickening. These values were then
assessed by linear regression analysis to define test reproduc-
ibility.
Cardiac event analysis. Cardiac events were defined as the
occurrence of sudden death, myocardial infarction, need for
revascularization and persistent allograft failure in the absence
of rejection. For the purpose of analysis, the association
between angioscopic plaque pigmentation and cardiac events
was evaluated by dividing the events into two groups: those
with sudden death and those with a nonsudden cardiac event,
as previously described.
Statistics. Comparisons of mean values for continuous
variable risk factors between groups were made using an
unpaired Student t test, whereas the chi-square or Fisher exact
test was used to find associations between categoric variables.
Further analysis of risk factors associated with either pig-
mented or nonpigmented intimal proliferation was performed
using linear regression analysis to assess significant correla-
tions with the degree of intimal thickness in these two distinct
morphologic groups. Those risk factors found to be significant
in the linear regression analysis were further examined by
using multivariate regression and independent relations of risk
factors with the degree of nonpigmented or pigmented intimal
thickening defined. This analysis was performed on an Apple
Macintosh computer using Statview IV software (Abacus
Concepts). All results were reported as mean value 6 SD. A p
value ,0.05 was considered significant.
Results
Clinical characteristics. The study group consisted of 73
men and 34 women whose mean age was 25 6 9 years (range
12 to 49). Thirty-two percent of the heart transplant recipients
had diabetes mellitus, 91% were hypertensive and 16% had
cytomegalovirus infection during the study period.
Analysis of immunologic factors revealed a 39% incidence
of treated cellular rejection, and HLAs were matched in 0.76 6
0.82 of the loci. Furthermore, the average daily cyclosporine
dose was 3.9 mg/kg per day, the average mean cyclosporine
level was 166 6 27 pg/dl, the average daily prednisone dose was
0.1 6 0.04 mg/kg per day, the cumulative prednisone consump-
tion was 12.7 6 5.6 g and the average daily azathioprine dose
was 1.27 6 0.5 mg/kg per day.
Intravascular ultrasound and intracoronary angioscopic
findings. Classification. The mean intimal thickness mea-
sured by intravascular ultrasound for the study group was
0.47 6 0.3 mm (range 0 to 1.6). Four patients had no
measurable intimal thickening and therefore were not ana-
lyzed further. The remaining 103 patients were classified into
two groups based on the angioscopic finding of either a
nonpigmented (white) surface or a pigmented (yellow) intimal
surface. Thus, 52% of patients had nonpigmented intimal
thickening, whereas 48% had pigmented intimal thickening
(p 5 NS). Moreover, pigmented intimal thickening was greater
in severity than the nonpigmented type (0.58 6 0.33 vs. 0.38 6
0.32 mm, p 5 0.006). Also, in patients with nonpigmented
disease, intimal thickening tended to be more diffuse and
concentric (88%) compared with nonpigmented thickening,
which was more often proximal and eccentric (69%).
Angioscopic surface texture. When surface contour was as-
sessed, 72% of nonpigmented surfaces were smooth compared
with only 18% of pigmented surfaces (p , 0.001). In contrast,
irregular surface contour was more prevalent in the pigmented
group (82%) compared with only 28% in the nonpigmented
group (p , 0.001). In addition, the plaques that were pig-
mented, yet irregular in surface appearance were bulkier
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(intimal thickness 0.65 mm) compared with the irregular, yet
nonpigmented variety (intimal thickness 0.27 mm, p 5 0.009).
Risk factor analysis. Donor age and a lower mean cyclo-
sporine level emerged as significant univariate correlates of
nonpigmented intimal hyperplasia, whereas time since trans-
plantation, serum cholesterol, cumulative prednisone dose and
number of HLA mismatches were significantly associated with
pigmented intimal thickening (Table 1).
Multivariate analysis demonstrated that time since trans-
plantation (p 5 0.003), cumulative prednisone consumption
(p 5 0.002) and HLA mismatches (p 5 0.03) independently
predicted the presence of pigmented intimal thickening. In
contrast, only donor age (p , 0.001) was independently
associated with the development of nonpigmented intimal
thickening.
Comparisons of risk factors between the two angioscopi-
cally defined groups revealed a longer time since transplanta-
tion (3.0 6 1.7 vs. 2.0 6 1.3 years, p 5 0.002), higher serum
cholesterol level (262 6 69 vs. 231 6 55 mg/dl, p 5 0.02),
higher low density lipoprotein cholesterol level (167 6 57 vs.
138 6 43 mg/dl, p 5 0.007) and a significantly higher incidence
of cellular rejection (46.2% vs. 29.6%, p 5 0.03) in the group
with pigmented intimal thickening compared with the group
with nonpigmented intimal thickening (Table 2).
Subgroup analysis of the pigmented variety of plaque with
reference to the association of risk factors and surface contour
was also delineated. Heart transplant recipients with pig-
mented, yet irregular plaque contour had a higher serum
cholesterol (272 vs. 208 mg/dl, p 5 0.03) and low density
lipoprotein cholesterol level (177 vs. 115 mg/dl, p 5 0.01) and
greater weight gain after transplantation (12% vs. 5%, p 5
0.02) (Table 3).
Test reproducibility. Intravascular ultrasound measure-
ments, expressed as a linear correlation, demonstrated intraob-
server and interobserver variabilities of 0.98 and 0.96, respec-
tively. Similarly, the interobserver variability for intracoronary
angioscopy was 0.96. Thus, test reproducibility for these imag-
ing modalities was excellent.
Cardiac events. The association between plaque pigmen-
tation and cardiac events in patients with cardiac allograft
vasculopathy was further examined. During the study, 30
cardiac events occurred, including 15 episodes of sudden
death, 8 myocardial infarctions, 2 percutaneous revasculariza-
tions resulting from atherectomy and stent implantation and 5
allograft failures in the absence of rejection. When the relation
of angioscopic plaque morphology was evaluated as a function
of two distinct cardiac event groups (those with sudden death
and those with nonsudden cardiac events), it was seen that the
nonsudden cardiac event group had a significantly higher
prevalence of pigmented plaque (80% vs. 47%, p 5 0.07). In
contrast, nonpigmented plaque was more frequently found in
the sudden death group (53% vs. 20%, p 5 0.05).
Discussion
Study findings. The results of this in vivo study using
intravascular ultrasound and intracoronary angioscopy provide
evidence for the presence of two distinct forms of cardiac
allograft vasculopathy. The first of these, characterized angio-
scopically as a pigmented variety, is predominantly influenced
by hyperlipidemia, weight gain, time elapsed after transplan-
tation, greater prednisone use and higher incidence of acute
allograft rejection. This variety demonstrates a predilection for
nonsudden cardiac events. In contrast, the second variety is a
nonpigmented type that occurs earlier after transplantation
and bears a direct relation with older donor age and lower
mean cyclosporine levels, and demonstrates a predilection for
sudden cardiac death. These findings emphasize the heteroge-
neity of cardiac allograft vasculopathy and suggest that this
entity has diverse morphologic expressions with different clin-
ical implications.
Histopathologic studies. The findings of this study parallel
histopathologic studies that have suggested the diversity of
cardiac allograft vasculopathy (1,2). An early investigation by
Johnson et al. (2) described a spectrum of coronary arterial
pathologic findings in 61 short- and long-term failed cardiac
Table 1. Predictors of Surface Morphology and Intimal Hyperplasia
Variable r Value p Value
Nonpigmented
Donor age 0.6 0.0001
Lower mean cyclosporine level 0.4 0.009
Pigmented
Time since transplantation 0.5 0.0008
Serum cholesterol 0.3 0.05
Cumulative prednisone dose 0.5 0.0009
HLA mismatches 0.4 0.03
HLA 5 human leucocyte antigen.
Table 2. Surface Morphology and Risk Factors
Nonpigmented Pigmented p Value
Smooth contour 72% 18% , 0.001
Irregular contour 28% 82% , 0.001
IT (mm) 0.38 6 0.32 0.58 6 0.33 0.006
Years after transplantation 2.0 6 1.3 3.0 6 1.7 0.002
Cholesterol (mg/dl) 231 6 55 262 6 69 0.02
LDL cholesterol (mg/dl) 138 6 43 167 6 57 0.007
Acute rejection 29.6% 46.2% 0.03
Data presented are mean value 6 SD, unless otherwise indicated. IT 5
intimal thickness; LDL 5 low density lipoprotein.
Table 3. Pigmented Hyperplasia: Surface Contour and Risk Factors
Irregular
Contour
Smooth
Contour
p
Value
IT (mm) 0.65 6 0.24 0.27 6 0.1 0.009
Cholesterol (mg/dl) 272 6 46 208 6 38 0.03
LDL cholesterol (mg/dl) 177 6 28 115 6 22 0.01
%weight gain after transplantation 12 6 3 5 6 3 0.02
Data presented are mean value 6 SD. Abbreviations as in Table 2.
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allografts. A range of findings from fibrous intimal thickening
in short-term allografts to fibrofatty atheromatous plaques in
longer surviving allografts became clearly evident; however,
this study did not assess the influence of potential risk factors
on these varied forms of cardiac allograft vasculopathy. The
use of intravascular ultrasound for detecting significant intimal
thickening and subsequent plaque characterization by angios-
copy enabled us not only to differentiate the two distinct forms
of cardiac allograft vasculopathy in vivo, but also to delineate
the differential influence of various putative risk factors on
their development.
Angioscopic findings—pigmented intimal proliferation.
The striking morphologic similarity of the pigmented variety of
intimal thickening with spontaneously occurring atherosclero-
sis is unmistakable (8). Indeed, the relation of hyperlipidemia
and weight gain after transplantation lends credence to this
observation. However, it should be emphasized that although
this distinct entity resembles spontaneous atherosclerosis, it
develops in a relatively short and accelerated duration of time.
Thus, although the pathogenic similarities may exist, the
association of acute allograft rejection with consequently
higher prednisone requirements and the resultant expression
of severe hyperlipidemia and weight gain may, in fact, account
for the rapid progression of this form of cardiac allograft
vasculopathy. Indeed, a study by Becker et al. (9) has provided
evidence that the cumulative dose of prednisone is one of the
strongest independent predictors of elevated serum cholesterol
and low density lipoprotein cholesterol after transplantation.
These findings are in agreement with our observations that a
constellation of higher HLA mismatches, allograft rejection,
prednisone use, weight gain and hyperlipidemia serve to
identify those heart transplant survivors with this form of
cardiac allograft vasculopathy.
Nonpigmented intimal proliferation. The nonpigmented
variety of intimal thickening is analogous to the fibrous form of
myointimal hyperplasia, which tends to develop earlier and is
concentric and longitudinally diffuse. We found a close corre-
lation between advanced donor age and lower mean cyclospor-
ine levels and the development of this distinct form of cardiac
allograft vasculopathy. An early study by Beiber et al. (10) that
evaluated complications in long-term cardiac allograft survi-
vors found an increased risk of cardiac allograft vasculopathy
in hearts from donors aged $35 years. In a related study that
analyzed risk factors for the major hazards after heart trans-
plantation, Scharples et al. (11) found that cardiac allografts
from donors aged $40 years had a greater relative risk of
developing cardiac allograft vasculopathy than grafts from
donors aged #20 years. Furthermore, in an intravascular
ultrasound investigation, our group previously demonstrated
that advanced donor age is a strong independent predictor of
the development of cardiac allograft vasculopathy (12).
Influence of immunosuppression. It was somewhat surpris-
ing, yet reassuring, to find that cyclosporine immunosuppres-
sion may exert a beneficial influence on the fibrous variety of
intimal hyperplasia. The prevailing school of thought suggests
that the incidence of cardiac allograft vasculopathy has not
decreased since the advent of cyclosporine immunosuppres-
sion (13). It is conceivable that although cyclosporine may
benefit the fibrous form of intimal thickening, it may facilitate
the development of the nonpigmented variety of intimal
hyperplasia through its deleterious lipid effects, thereby not
altering the incidence of cardiac allograft vasculopathy as a
whole (14). Thus, our study helps in the identification of a
subgroup of heart transplant recipients who may most likely
benefit from augmented cyclosporine immunosuppression.
Clinical outcomes: morphologic correlates. Another in-
triguing observation relates to the fact that the characteristics
and modalities of cardiac events bear an important relation to
angioscopic plaque pigmentation. As the results of this study
indicate, heart transplant recipients with sudden death were
more likely to demonstrate a higher prevalence of nonpig-
mented plaque, whereas the group of patients who had non-
sudden death events (myocardial infarction, need for revascu-
larization and allograft failure) had a higher occurrence of
pigmented plaques. These findings once again emphasize that
cardiac allograft vasculopathy consists of two morphologic
varieties of disease entities, and that these two distinct mor-
phologic presentations might have disparate clinical event
predilections, and thereby different prognostic implications.
In addition, the knowledge that distinct subsets of cardiac
allograft vasculopathy exist may allow the clinician to target
both forms of the disease in an attempt to decrease the overall
incidence of this devastating disorder. Consequently, there
have been data demonstrating the benefit of using lipid-
lowering therapy in heart transplant recipients (15). Also, in a
recent angiographic study, Kobashigawa et al. (16) alluded to
the lower incidence of cardiac allograft vasculopathy in pa-
tients successfully weaned from corticosteroids. The impor-
tance of higher cyclosporine levels of immunosuppression and
its relation to cardiac allograft vasculopathy need further
elucidation.
Study limitations. The question of whether these two
distinct forms of cardiac allograft vasculopathy represent sep-
arate disease processes or merely a continuum remains unre-
solved because of the cross-sectional nature of this investiga-
tion. However, we examined a group of 21 patients who
underwent serial angioscopic studies and, with the exception of
two patients, found no significant morphologic changes sug-
gestive of a shift in plaque variety with time. Furthermore,
pathologic studies have also alluded to the presence of distinct
morphologic forms of cardiac allograft vasculopathy (2).
Another limitation of angioscopic analysis lies in its lack of
peripheral imaging, as it is only capable of imaging the
proximal vasculature.
A final limitation that cannot be entirely reconciled relates
to the lack of the presence of baseline angioscopic evaluation
in most patients, which could have reliably allowed the exclu-
sion of donor-transmitted disease as a contributor to the
different plaque morphologic findings. However, coupled with
the unique clinical event predilections, the striking clinical
differences suggest that the two distinct angioscopic morpho-
logic findings were hardly affected by this limitation.
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Conclusions. This study demonstrates that intracoronary
angioscopy is complementary to intravascular ultrasound in the
morphologic characterization of cardiac allograft vasculopathy
and provides insight into the diverse effects of nonimmuno-
logic and immunologic risk factors, particularly the impact of
immunosuppression, in two distinct forms of this disease.
Furthermore, this investigation demonstrates that these two
heterogeneous forms of cardiac allograft vasculopathy might
have disparate prognostic and therapeutic implications.
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